Clovis Oncology Stock Forecast, Price & News

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

Is Clovis Oncology a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Clovis Oncology stock.
View analyst ratings for Clovis Oncology or view top-rated stocks.

How has Clovis Oncology's stock been impacted by Coronavirus?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLVS shares have decreased by 50.4% and is now trading at $3.06.
View which stocks have been most impacted by COVID-19.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Clovis Oncology.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.08. The biopharmaceutical company earned $37.92 million during the quarter, compared to the consensus estimate of $38.73 million. During the same quarter last year, the company earned ($0.89) earnings per share.
View Clovis Oncology's earnings history.

What price target have analysts set for CLVS?

2 analysts have issued 1-year price targets for Clovis Oncology's stock. Their forecasts range from $4.75 to $9.00. On average, they expect Clovis Oncology's share price to reach $6.88 in the next twelve months. This suggests a possible upside of 124.7% from the stock's current price.
View analysts' price targets for Clovis Oncology or view top-rated stocks among Wall Street analysts.

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:

• Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
• Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64) (LinkedIn Profile)
• Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
• Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
• Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Clovis Oncology's key competitors?

Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Novavax (NVAX), Exact Sciences (EXAS), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of CLVS's competitors.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (1.55%), UBS Group AG (0.73%), Rafferty Asset Management LLC (0.55%), Principal Financial Group Inc. (0.53%), Pinnacle Associates Ltd. (0.56%) and Millennium Management LLC (0.45%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding.
View institutional ownership trends for Clovis Oncology.

Which major investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Russell Investments Group Ltd., Deutsche Bank AG, Citadel Advisors LLC, Cubist Systematic Strategies LLC, Natixis, Jane Street Group LLC, and State Board of Administration of Florida Retirement System. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, Paul Edward Gross, and Thomas C Harding.
View insider buying and selling activity for Clovis Oncology or view top insider-selling stocks.

Which major investors are buying Clovis Oncology stock?

CLVS stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Rafferty Asset Management LLC, Geode Capital Management LLC, Alliancebernstein L.P., Goldman Sachs Group Inc., Renaissance Technologies LLC, Wolverine Asset Management LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Clovis Oncology or or view top insider-buying stocks.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $3.06.

How much money does Clovis Oncology make?

Clovis Oncology has a market capitalization of $397.74 million and generates $164.52 million in revenue each year. The biopharmaceutical company earns $-369.21 million in net income (profit) each year or ($2.83) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

Where are Clovis Oncology's headquarters?

Clovis Oncology is headquartered at 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at [email protected], or via fax at 303-245-0360.